These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 16084463

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome.
    Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, Rhee JC.
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):71-8. PubMed ID: 16706815
    [Abstract] [Full Text] [Related]

  • 3. Interactions between symptoms and motor and visceral sensory responses of irritable bowel syndrome patients to spasmolytics (antispasmodics).
    Khalif IL, Quigley EM, Makarchuk PA, Golovenko OV, Podmarenkova LF, Dzhanayev YA.
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):17-22. PubMed ID: 19337628
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [Abstract] [Full Text] [Related]

  • 6. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P, Dapoigny M, Bonaz B, Siproudhis L.
    Aliment Pharmacol Ther; 2005 Feb 15; 21(4):435-44. PubMed ID: 15709995
    [Abstract] [Full Text] [Related]

  • 7. Treatment of refractory irritable bowel syndrome with visceral osteopathy: short-term and long-term results of a randomized trial.
    Attali TV, Bouchoucha M, Benamouzig R.
    J Dig Dis; 2013 Dec 15; 14(12):654-61. PubMed ID: 23981319
    [Abstract] [Full Text] [Related]

  • 8. Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes.
    Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ, Isaacs NJ, Maldeniya L, Martin CM, Persson J, Andrews JM, Holtmann G, Blackshaw LA, Brierley SM.
    Gut; 2013 Oct 15; 62(10):1456-65. PubMed ID: 22767422
    [Abstract] [Full Text] [Related]

  • 9. Bloating and distention in irritable bowel syndrome: the role of visceral sensation.
    Agrawal A, Houghton LA, Lea R, Morris J, Reilly B, Whorwell PJ.
    Gastroenterology; 2008 Jun 15; 134(7):1882-9. PubMed ID: 18455167
    [Abstract] [Full Text] [Related]

  • 10. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
    Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G.
    Am J Gastroenterol; 2011 Jul 15; 106(7):1290-8. PubMed ID: 21427712
    [Abstract] [Full Text] [Related]

  • 11. Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.
    Tuteja AK, Fang JC, Al-Suqi M, Stoddard GJ, Hale DC.
    Scand J Gastroenterol; 2012 Oct 15; 47(10):1159-64. PubMed ID: 22783919
    [Abstract] [Full Text] [Related]

  • 12. Clinical trial: transcutaneous interferential electrical stimulation in individuals with irritable bowel syndrome - a prospective double-blind randomized study.
    Coban Ş, Akbal E, Köklü S, Köklü G, Ulaşlı MA, Erkeç S, Aktaş B, Yüksel O, Koçak E, Erdem HR.
    Digestion; 2012 Oct 15; 86(2):86-93. PubMed ID: 22846190
    [Abstract] [Full Text] [Related]

  • 13. Visceral hypersensitivity in irritable bowel syndrome.
    Kanazawa M, Hongo M, Fukudo S.
    J Gastroenterol Hepatol; 2011 Apr 15; 26 Suppl 3():119-21. PubMed ID: 21443723
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY, Lu CL, Chen CY, Luo JC.
    J Gastroenterol Hepatol; 2007 Dec 15; 22(12):2266-72. PubMed ID: 17559369
    [Abstract] [Full Text] [Related]

  • 15. Randomised clinical trial: the clinical effects of a novel neurokinin receptor antagonist, DNK333, in women with diarrhoea-predominant irritable bowel syndrome.
    Zakko S, Barton G, Weber E, Dunger-Baldauf C, Rühl A.
    Aliment Pharmacol Ther; 2011 Jun 15; 33(12):1311-21. PubMed ID: 21507028
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
    Yu FY, Huang SG, Zhang HY, Ye H, Chi HG, Zou Y, Lv RX, Zheng XB.
    World J Gastroenterol; 2016 Mar 28; 22(12):3451-9. PubMed ID: 27022227
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S, Bieuvelet S, Burckel A, Cazaubiel M, Dray X, Marteau P.
    Gastroenterol Clin Biol; 2008 Feb 28; 32(2):147-52. PubMed ID: 18387426
    [Abstract] [Full Text] [Related]

  • 20. Abdominal pain impacts quality of life in women with irritable bowel syndrome.
    Cain KC, Headstrom P, Jarrett ME, Motzer SA, Park H, Burr RL, Surawicz CM, Heitkemper MM.
    Am J Gastroenterol; 2006 Jan 28; 101(1):124-32. PubMed ID: 16405544
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.